Modelling efforts needed to advance herpes simplex virus (HSV) vaccine development: Key findings from the World Health Organization Consultation on HSV Vaccine Impact Modelling

Publication date: Available online 21 June 2017
Source:Vaccine
Author(s): Sami L. Gottlieb, Birgitte Giersing, Marie-Claude Boily, Harrell Chesson, Katharine J. Looker, Joshua Schiffer, Ian Spicknall, Raymond Hutubessy, Nathalie Broutet
Development of a vaccine against herpes simplex virus (HSV) is an important goal for global sexual and reproductive health. In order to more precisely define the health and economic burden of HSV infection and the theoretical impact and cost-effectiveness of an HSV vaccine, in 2015 the World Health Organization convened an expert consultation meeting on HSV vaccine impact modelling. The experts reviewed existing model-based estimates and dynamic models of HSV infection to outline critical future modelling needs to inform development of a comprehensive business case and preferred product characteristics for an HSV vaccine. This article summarizes key findings and discussions from the meeting on modelling needs related to HSV burden, costs, and vaccine impact, essential data needs to carry out those models, and important model components and parameters.



http://ift.tt/2sTVhGk